Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BMS 986192

Drug Profile

BMS 986192

Alternative Names: [18F]BMS-986192; Anti-PD-L1 - Bristol-Myers Squibb; BMS-986192

Latest Information Update: 25 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Programmed cell death-1 ligand-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Non-small cell lung cancer

Most Recent Events

  • 28 Jul 2019 No recent reports of development identified for clinical-Phase-Unknown development in Non-small-cell-lung-cancer(Combination therapy, Late-stage disease, Second-line therapy or greater) in Netherlands (IV, Infusion)
  • 01 Apr 2017 Interim pharmacodynamics data from preclinical studies in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 01 Jun 2016 Clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in Netherlands (IV) (EudraCT2015-004760-11)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top